文 献 8）Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet 2022; 399: 1401-10. 9）Azizi M, Sharp ASP, Fisher NDL, Weber MA, Lobo MD, Daemen J, et al. Patient-level pooled analysis of endovascular ultrasound renal denervation or a sham procedure 6 months after medication escalation: The RADIANCE Clinical Trial Program. Circulation 2024; 149: 747-59.10）Kario K, Ogawa H, Okumura K, Okura T, Saito S, Ueno T, et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in asian patients -. Circ J 2015; 79: 1222-9.11）Katsurada K, Kario K. Emerging topics on renal denervation in hypertension: anatomical and functional aspects of renal nerves. Hypertens Res 2023; 46: 1462-70.12）Katsurada K, Ogoyama Y, Imai Y, Patel KP, Kario K. Renal denervation based on experimental rationale. Hypertens Res 2021; 44: 1385-94.13）Kusayama T, Wong J, Liu X, He W, Doytchinova A, Robinson EA, et al. Simultaneous noninvasive recording of electrocardiogram and skin sympathetic nerve activity (neuECG). Nat protocol 2020; 15: 1853-77. 1）Kario K, Tomotani N, Wang TD, Park S, Li Y, Shin J, et al. Home blood pressure-centered approach - from digital health to medical practice: HOPE Asia Network consensus statement 2023. Hypertens Res 2023; 46: 2561-74. 2）Kario K, Hoshide S, Narita K, Okawara Y, Kanegae H, Investigator’s network. Cardiovascular prognosis in drug-resistant hypertension stratified by 24-hour ambulatory blood pressure: The JAMP Study. Hypertension 2021; 78: 1781-90. 3）Narita K, Hoshide S, Kario K. Association of treatment-resistant hypertension defined by home blood pressure monitoring with cardiovascular outcome. Hypertens Res 2022; 45: 75-86. 4）Narita K, Hoshide S, Kario K. Nighttime home blood pressure is associated with the cardiovascular disease events risk in treatment-resistant hypertension. Hypertension 2022; 79: e18-20. 5）Ogoyama Y, Abe M, Okamura K, Tada K, Katsurada K, Shibata S, et al. Effects of renal denervation on blood pressure in patients with hypertension: a latest systematic review and meta-analysis of randomized sham-controlled trials. Hypertens Res 2024; 47: 2745-59. 6）Mahfoud F, Bohm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L, et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J 2019; 40: 3474-82. 7）Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet 2022; 400: 1405-16.治療抵抗性高血圧に及ぼす交感神経亢進の影響67
元のページ ../index.html#83